Genmab And Paradigm Therapeutics Announce Major Alliance on Discovery Targets for Human Amtibody Therapeutics
Copenhagen, Denmark – 11 April, 2002 Genmab A/S and the privately owned Cambridge, UK based Paradigm Therapeutics Ltd today announced the formation of a broad-based collaboration to develop new antibody therapeutic products. The partnership will utilize novel commercially promising disease targets discovered in Paradigm’s research combined with Genmab’s fully human antibody technology to create and develop new products.
The alliance will cover a broad range of disease areas including cancer and inflammatory diseases. The collaboration brings together Paradigm’s sophisticated combination of bioinformatics and functional biology - with Genmab’s broad antibody development capabilities and extensive array of pre-clinical tools to generate and characterize fully human antibodies. Genmab and Paradigm will collaborate on the research, development and commercializsation of the new antibody products and will share development costs and revenues generated from out-licensing or sales of these products. The diseases covered by the alliance include many of the most common and devastating afflictions in the US, Europe and around the world.
“We are immensely pleased to have signed this deal with Paradigm, which continues our strategy of maintaining a broad pipeline of products,” said Lisa N. Drakeman, Ph.D., Genmab’s Chief Executive Officer. “Our partnering strategy helps Genmab move into position as one of the industry leaders in developing urgently needed antibody treatments for patients.”
“Paradigm has established a powerful biological platform to define the potential clinical utility of large numbers of novel human drugable gene targets and is now ideally positioned to start the development of drugs to these targets,. “ said Dr Richard Goodfellow, Commercial Director at Paradigm. “The short development time for monoclonal antibody drugs offers Paradigm the opportunity to start clinical trials on antibody products directed against Paradigm’s targets within 2 years or less – a considerably shorter development period than for small molecule drugs. We are therefore delighted to have forged an alliance with Genmab, to exploit the huge potential for generating exciting monoclonal antibody therapeutic drugs to Paradigm’s targets.”.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
